Home

Prelude Therapeutics is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, small molecule therapies that precisely target the key drivers of cancer cell growth and resistance. With our core competencies in cancer biology, medicinal chemistry, and drug development, we are rapidly translating our discoveries into potential treatments that offer hope to patients with cancer.

A Bold, Scientific Approach to the Discovery & Development of Innovative Medicines

The discovery of a new medicine is a complex journey of innovation, determination, and insight where both biology and chemistry orchestrate a potential solution for patients. At Prelude Therapeutics, we go where the science leads us, not constrained within a platform, or by a specific target class or chemical modality, to solve challenging, unmet needs of patients. We strive to turn our scientific insights into safe and effective drugs to improve the lives of people with cancer.

Take a look at what we have achieved and how we were able to do it »

CDK9 is a cyclin dependent kinase and an essential regulator of cancer-promoting transcriptional programs
Potentially Best-in-Class Selectivity
Potential to avoid off-target toxicity and higher clinical activity

Learn More »

circle graphic

CDK9 is a cyclin dependent kinase and an essential regulator of cancer-promoting transcriptional programs
Potentially Best-in-Class Selectivity
Potential to avoid off-target toxicity and higher clinical activity

Learn More »

Prelude and its partner AbCellera to develop potent degraders/inhibitors as payloads for novel antibodies targeting tumor specific antigens
Next generation ADCs to extend the therapeutic utility of this class.

Learn More »

CDK4 and CDK6 play a central role in cell cycle regulation, dysregulation of the CDK4/CDK6 pathway as potential therapeutic targets for cancer treatment
Highly Selective CDK4 Bias
Potential for high tissue and brain penetration and better combinability

Learn More »

SMARCA2 protein degraders designed to be synthetic lethal to SMARCA4 deletion that occur in a wide range of cancers
Potent and Selective Degrader
Potential to address major unmet need in biomarker-selected patients

Learn More »

Our Clinical Trials

Innovations in research and discovery, improved technologies, a deeper understanding of cancer biology and behavior, and novel scientific approaches are providing new hope for patients. The Prelude team is proud to have advanced several transformational cancer therapies for patients and we are rapidly moving additional novel therapeutics into clinical trials.

See Our Clinical Trials »

Our Team

With multiple, diverse first/best-in-class programs already in the clinic, we feel the urgency of applying our team’s expertise to finding the therapies that transform patients’ lives. Our cause is cancer, our purpose is patients, and we strive to develop safe, effective, and durable treatments to help improve patients’ lives.

Join Our Team»

Press Releases

May 8, 2023

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Read More »

April 11, 2023

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Read More »

March 15, 2023

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Read More »